18 F‑FD4
α‑Synuclein aggregation imaging in Parkinson's disease and multiple system atrophy
Phase 1Active
Key Facts
Indication
α‑Synuclein aggregation imaging in Parkinson's disease and multiple system atrophy
Phase
Phase 1
Status
Active
Company
About SynuSight
Biotech startup creating AI‑enhanced imaging and therapeutics for protein‑misfolding neurodegenerative disorders.
View full company profile